AstraZeneca proposes a direct NYSE listing to broaden its global investor base and simplify access for U.S. investors, while the company's Enhertu drug shows promising results.
AstraZeneca proposes a direct NYSE listing to broaden its global investor base and simplify access for U.S. investors, while the company's Enhertu drug shows promising results.